Clinical Scorecard: Comparative Phase 3 Analysis of SB16, a Proposed Biosimilar to Denosumab, Against Reference Denosumab in Women with Postmenopausal Osteoporosis: Results Through 12 Months
At a Glance
Category
Detail
Condition
Postmenopausal osteoporosis characterized by decreased bone mass and increased fracture risk
Key Mechanisms
Denosumab and SB16 inhibit RANK ligand, reducing osteoclast activity and bone resorption, thereby increasing bone density
Target Population
Postmenopausal women aged 55-80 years with lumbar spine or total hip T-score between −2.5 and −4
Care Setting
Multicenter clinical trial setting with subcutaneous administration of treatment
Key Highlights
SB16 demonstrated biosimilarity to reference denosumab in efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity over 12 months
Primary endpoint: Percent change from baseline in lumbar spine BMD at month 12 showed equivalence within predefined margins
Study included 457 treatment-naïve postmenopausal osteoporosis patients randomized 1:1 to SB16 or denosumab
Guideline-Based Recommendations
Diagnosis
Diagnosis based on BMD T-score between −2.5 and −4 at lumbar spine or total hip
Exclude patients with severe vertebral fractures, hip fractures, or significant renal impairment
Confirm postmenopausal status by absence of menstruation for at least 12 months
Management
Administer 60 mg subcutaneous injections of denosumab or biosimilar SB16 at baseline and 6 months
Ensure daily supplementation with at least 1 g elemental calcium and 800 IU vitamin D
Consider biosimilar SB16 as an alternative to reference denosumab based on demonstrated equivalence
Monitoring & Follow-up
Monitor bone mineral density at lumbar spine, total hip, and femoral neck periodically
Assess pharmacodynamic markers such as serum C-telopeptide and procollagen type I N-terminal propeptide
Evaluate safety and immunogenicity profiles throughout treatment
Risks
Exclude patients with serum 25-hydroxyvitamin D <20 ng/mL or abnormal serum calcium levels
Avoid use in patients with prior long-term bisphosphonate use or recent use within 1 year
Monitor for potential adverse events related to monoclonal antibody therapy
Patient & Prescribing Data
Postmenopausal women with osteoporosis, treatment-naïve to biologic therapies
SB16 provides comparable efficacy and safety to denosumab, supporting its use as a biosimilar alternative
Clinical Best Practices
Confirm eligibility with precise BMD measurements and exclusion criteria before initiating treatment
Maintain adequate calcium and vitamin D supplementation during therapy
Use randomized, double-blind protocols to assess biosimilarity in clinical trials
Monitor bone turnover markers and immunogenicity to ensure treatment safety and effectiveness
by Bente Langdahl, Yoon-Sok Chung, Rafal Plebanski, Edward Czerwinski, Eva Dokoupilova, Jerzy Supronik, Jan Rosa, Andrzej Mydlak, Anna Rowińska-Osuch, Ki-Hyun Baek, Audrone Urboniene, Robert Mordaka, Sohui Ahn, Young Hee Rho, Jisuk Ban, Richard Eastell
